Lin BioScience, Inc. (TPEX:6696)
399.50
+18.00 (4.72%)
Jun 5, 2026, 1:55 PM CST
Lin BioScience Market Cap
Lin BioScience has a market cap or net worth of 33.09 billion as of June 5, 2026. Its market cap has increased by 239.19% in one year.
Market Cap
33.09B
Enterprise Value
31.22B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
399.50
Market Cap Chart
Since October 8, 2018, Lin BioScience's market cap has increased from 2.92B to 33.09B, an increase of 1,034.72%. That is a compound annual growth rate of 37.31%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 4, 2026 | 31.60B | -3.79% |
| Dec 31, 2025 | 32.84B | 203.76% |
| Dec 31, 2024 | 10.81B | 20.85% |
| Dec 29, 2023 | 8.95B | -28.90% |
| Dec 30, 2022 | 12.58B | -1.94% |
| Dec 30, 2021 | 12.83B | 83.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Oct 8, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Pell Bio-Med Technology | 40.84B |
| Oneness Biotech | 24.54B |
| Lumosa Therapeutics | 20.77B |
| Sunmax Biotechnology | 20.67B |
| CHO Pharma | 15.04B |
| Medigen Vaccine Biologics | 14.81B |
| TaiMed Biologics | 14.40B |
| EirGenix | 13.33B |